AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an IL-13 receptor α-chain comprising the amino acid sequence set forth in SEQ ID NO:4 or a nucleotide sequence encoding a derivative of said IL-13 receptor α-chain, wherein the derivative is an extracellular domain of the IL-13 receptor α-chain comprising amino acids 28-346 of SEQ ID No: 4 or comprising an amino acid sequence having at least 95% identity with amino acids 28-346 of SEQ ID No: 4, and wherein said derivative binds with IL-13 or is immunologically interactive with antibodies to said IL-13 receptor alpha chain.
- 2. (Currently amended) An isolated nucleic acid molecule comprising a nucleotide sequence encoding an IL-13 receptor α chain comprising an amino acid sequence as set forth in SEQ ID NO:4 or a nucleotide sequence encoding a derivative of said an IL-13 receptor α -chain, wherein said receptor α -chain comprises the amino acid sequence as set forth in SEQ ID NO: 4,:
 - (i) binds with IL-13 or its derivatives; and
- (ii) binds with a complex between IL-4 and IL-4 receptor α-chain, and wherein the derivative is an extracellular domain of the IL-13 receptor α-chain comprising comprises amino acids 28-34628-342 of SEQ ID NoNO: 4 or comprising comprises an amino acid sequence having at least 95% identity with amino acids 28-34628-342 of SEQ ID NoNO: 4, and wherein said derivative binds with IL-13 or is immunologically interactive with antibodies to said IL-13 receptor alpha chain.

3-6. (Cancelled)

7. (Currently amended) An isolated nucleic acid molecule comprising a sequence of nucleotides which encodes an IL-13 receptor α-chain or a derivative thereof, said nucleic acid molecule having acomprising the nucleotide sequence as set forth in SEQ ID NO: 3 or having comprising a nucleotide sequence which hybridizes to the complement of the nucleotide sequence as set forth in SEQ ID NO: 3 under low stringency conditions, wherein said low

stringency conditions comprise <u>hybridization in 5x SSC at 50°C and washing in 0.2x SSC at 50°C6x SSC</u>, 0.1% w/v SDS at 42°C, and wherein the derivative is an extracellular domain of the IL-13 receptor & chain comprising amino acids 28-346 of SEQ ID No: 4 or comprising an amino acid sequence having at least 95% identity with amino acids 28-346 of SEQ ID No: 4, and wherein said derivative binds with IL-13 or is immunologically interactive with antibodies to said IL-13 receptor alpha chain.

8-9. (Cancelled)

10. (Currently amended) An expression vector comprising a nucleic acid molecule according to elaim 1 or 7 any one of claims 1, 2 or 7, operably linked to a promoter which directs expression of said nucleic acid molecule in a host cell.

11-24. (Cancelled)

25. (Currently amended) A composition comprising a nucleic acid molecule according to claim 1 or 2 or 7 or 8 any one of claims 1, 2 or 7, and a pharmaceutically acceptable carrier.

26-27. (Cancelled)

- 28. (Currently amended) A method of producing a recombinant polypeptide having at least two of the following characteristics:
 - (i) comprises anthe amino acid sequence as set forth in SEQ ID NO:4;
 - (ii) is encoded by athe nucleotide sequence as set forth in SEQ ID NO:3;
 - (iii) binds with IL-13 or its derivatives; and
 - (iv) said polypeptide, when expressed in COS cells, has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis,

said method comprising culturing cells comprising the expression vector according to claim 10 for a time and under conditions sufficient to express the nucleic acid molecule in said expression vector to produce a recombinant polypeptide and isolating said recombinant polypeptide.

- 29. (Currently amended) A method of producing a recombinant polypeptide having at least three of the following characteristics:
 - (i) comprises anthe amino acid sequence as set forth in SEQ ID NO:4;
 - (ii) is encoded by athe nucleotide sequence as set forth in SEQ ID NO:3;
 - (iii) binds with IL-13 or its derivatives;
 - (iv) said polypeptide, when expressed in COS cells, has a molecular weight of from about 50,000 to about 70,000 daltons as determined by Western blot analysis;
 - (v) comprises an amino acid sequence derived from IL-4 receptor α-chain; and
 - (vi) is capable of interaction with IL-13 which is competitively inhibited by IL-4 in cells which express an IL-4 receptor α-chain,

said method comprising culturing cells comprising the expression vector according to claim 10 for a time and under conditions sufficient to express the nucleic acid molecule in said expression vector to produce a recombinant polypeptide and isolating said recombinant polypeptide.

30-36. (Cancelled)

37. (Previously Presented) An isolated nucleic acid molecule comprising the nucleotide sequence as set forth in SEQ ID NO: 3.

38-42. (Cancelled)

- 43. (Currently amended) The isolated nucleic acid molecule of claim 12, encoding a polypeptide consisting of amino acids 28-34628-342 of SEQ ID NO: 4.
- 44. (Previously Presented) The isolated nucleic acid molecule of claim 1, encoding a polypeptide consisting of amino acids 28-426 of SEQ ID NO:4.

45-46. (Cancelled)

47. (Previously Presented) A method of producing a recombinant polypeptide comprising culturing cells comprising the expression vector according to claim 10 for a time and

under conditions sufficient to express a polypeptide encoded by said expression vector and isolating said recombinant polypeptide.

- 48. (Currently amended) The isolated nucleic acid sequence of claim +2 wherein said sequence consists of nucleotides +42-1098142-1086 of SEQ ID NO: 3.
- 49. (Previously Presented) The isolated nucleic acid sequence of claim 1 wherein said sequence consists of nucleotides 142-1338 of SEQ ID NO: 3.
 - 50-52. (Cancelled)
 - 53. (New) An isolated host cell transformed with the expression vector of claim 10.
- 54. (New) An isolated host cell which expresses a recombinant polypeptide encoded by a nucleic acid molecule according to any one of claims 1, 2 or 7.